The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function
Open accessAbstract
NKp30, a natural cytotoxicity receptor expressed on NK cells is critically involved in direct cytotoxicity against various tumor cells and directs both maturation and selective killing of dendritic cells. Recently the intracellular protein BAT3, which is involved in DNA damage induced apoptosis, was identified as a ligand for NKp30. However, the mechanisms underlying the exposure of the intracellular ligand BAT3 to surface NKp30 and its role in NK-DC cross talk remained elusive. Electron microscopy and flow cytometry demonstrate that exosomes released from 293T cells and iDCs express BAT3 on the surface and are recognized by NKp30-Ig. Overexpression and depletion of BAT3 in 293T cells directly correlates with the exosomal expression level and the activation of NK cell-mediated cytokine release. Furthermore, the NKp30-mediated NK/DC cross talk resulting either in iDC killing or maturation was BAT3-dependent. Taken together this puts forward a new model for the activation of NK cells through intracellular signals that are released via exosomes from accessory cells. The manipulation of the exosomal regulation may offer a novel strategy to induce tumor immunity or inhibit autoimmune diseases caused by NK cell-activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 2×
“are membrane micro-vesicles (diameter of 50–100 nm) [17] with”
BackgroundTumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Théry, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001) · Nature Medicine · doi:10.1038/85438 · Cited by 1,640
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Pan, B. T., Teng, K., Wu, C., Adam, M., & Johnstone, R. M. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.3.942 · Cited by 1,241
Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M., & Münz, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011149 · Cited by 994
Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes
Théry, C., Duban, L., Segura, E., Véron, P., Lantz, O., & Amigorena, S. (2002) · Nature Immunology · doi:10.1038/ni854 · Cited by 960
Malignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Bryceson, Y. T., March, M. E., Ljunggren, H.-G., & Long, E. O. (2006) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
Cited by
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
“To confer targeting capabilities, we fused targeting peptides for muscle and brain, two tissues affected by degenerative diseases amenable to gene therapy, to the extra-exosomal N terminus of murine Lamp2b, a protein found abundantly in exosomal membrane”
BackgroundMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,801
Engineering exosomes for targeted drug delivery
Liang, Y., Duan, L., Lu, J., & Xia, J. (2021) · Theranostics · doi:10.7150/thno.52570 · Cited by 1,547
“Researchers proved that the N-terminus of LAMP-2B is displayed on the surface of exosomes and can be appended with targeting sequences [35, 43].”
BackgroundEngineering exosomes as refined biological nanoplatforms for drug delivery
Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.12 · Cited by 1,163
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
Besse, B., Charrier, M., Lapierre, V., Dansin, E., Lantz, O., Planchard, D., Le Chevalier, T., Livartoski, A., Barlesi, F., Laplanche, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1071008 · Cited by 749
Self-citationExosomes and other extracellular vesicles in host–pathogen interactions
Schorey, J. S., Cheng, Y., Singh, P. P., & Smith, V. L. (2015) · EMBO reports · doi:10.15252/embr.201439363 · Cited by 727
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Dendritic cell-derived exosomes for cancer therapy.
Pitt, J. M., André, F., Amigorena, S., Soria, J.-C., Eggermont, A., Kroemer, G., & Zitvogel, L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81137 · Cited by 636
Zhu, X., Badawi, M., Pomeroy, S., Sutaria, D. S., Xie, Z., Baek, A., Jiang, J., Elgamal, O. A., Mo, X., La Perle, K., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1324730 · Cited by 582
Exosomes as intercellular signalosomes and pharmacological effectors
Record, M., Subra, C., Silvente-Poirot, S., & Poirot, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.011 · Cited by 537
Exosomes: From Garbage Bins to Promising Therapeutic Targets
H. Rashed, M., Bayraktar, E., K. Helal, G., Abd-Ellah, M., Amero, P., Chavez-Reyes, A., & Rodriguez-Aguayo, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030538 · Cited by 525
Salunkhe, S., Dheeraj, Basak, M., Chitkara, D., & Mittal, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.042 · Cited by 497
Wang, P., Wang, H., Huang, Q., Peng, C., Yao, L., Chen, H., Qiu, Z., Wu, Y., Wang, L., & Chen, W. (2019) · Theranostics · doi:10.7150/thno.30716 · Cited by 494
Viaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
The Natural Cytotoxicity Receptors in Health and Disease
Barrow, A. D., Martin, C. J., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00909 · Cited by 370
Bellavia, D., Raimondo, S., Calabrese, G., Forte, S., Cristaldi, M., Patinella, A., Memeo, L., Manno, M., Raccosta, S., Diana, P., et al. (2017) · Theranostics · doi:10.7150/thno.17092 · Cited by 368
Transfer of extracellular vesicles during immune cell‐cell interactions
Gutiérrez‐Vázquez, C., Villarroya‐Beltri, C., Mittelbrunn, M., & Sánchez‐Madrid, F. (2013) · Immunological Reviews · doi:10.1111/imr.12013 · Cited by 323
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Koch, J., Steinle, A., Watzl, C., & Mandelboim, O. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.01.003 · Cited by 317
Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer
Pitt, J. M., Charrier, M., Viaud, S., André, F., Besse, B., Chaput, N., & Zitvogel, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400703 · Cited by 296
Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers
Das, C. K., Jena, B. C., Banerjee, I., Das, S., Parekh, A., Bhutia, S. K., & Mandal, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00901 · Cited by 263
LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles
Qiao, L., Hu, J., Qiu, X., Wang, C., Peng, J., Zhang, C., Zhang, M., Lu, H., & Chen, W. (2023) · Autophagy · doi:10.1080/15548627.2023.2235196 · Cited by 174
Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy
Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K. Y., Choi, Y., Kim, S. H., & Yang, Y. (2021) · Cancers · doi:10.3390/cancers13174435 · Cited by 152
“Third, DEX express the ligand peptides that activate NK cells on their surface [36,38,39].”
BackgroundHarnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
Metadata
- Authors
- Simhadri, V. R., Reiners, K. S., Hansen, H. P., Topolar, D., Simhadri, V. L., Nohroudi, K., Kufer, T. A., Engert, A., & Pogge von Strandmann, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-10-13
- Volume
- 3
- Issue
- 10
- Pages
- e3377
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1971411291
- Cited by
- 262
- References
- 37
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.